The efficacy and safety of enzalutamide for castrate-resistant prostate cancer patient showing disease progression after or during chemotherapy including docetaxel.

The efficacy and safety of enzalutamide for castrate-resistant prostate cancer patient showing disease progression after or during chemotherapy including docetaxel. - The efficacy and safety of enzalutamide on castrate-resistant prostate cancer after docetaxel treatment.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023627

Enrollment

Registered

2016-08-16

Start date

2014-07-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castrate-resistant prostate cancer

Interventions

Enzalutamide administration

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) histologically diagnosed as prostate cancer. 2) on-going androgen-deprivation therapy by either GnRH analogue or surgical castration. 3) judged as progressive disease after chemotherapy including docetaxel with concomitant medical castration or after surgical castration.

Exclusion criteria

Exclusion criteria: 1) contraindication for enzalutamide 2) history of seizure (including febrile seizure), loss of consciousness. 3) symptom of temporal brain ischemia or warning sign of seizure within a year 4) judged as inappropriate by the investigator.

Design outcomes

Primary

Measure	Time frame
PSA response rate	—

Secondary

Measure	Time frame
duration of PSA response Overall Survival QOL (FACT-P) Adverse Events	—

Countries

Japan

Contacts

Public ContactYoshiaki Kawano

Faculty of Life Sciences, Kumamoto University Department of Urology

urology@kumamoto-u.ac.jp096-373-5240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026